MAPT and neurodegenerative disease: Based on these results, it is reasonable to anticipate that SCGN would indeed protect other aggregation-prone proteins, specifically those implicated in neurodegenerative diseases, such as Aβ-42 and Tau from undergoing fibrillogenesis.